Display options
Cite
Doğru A, Ugan Y, Şahin M, et al. Catastrophic antiphospholipid syndrome treated with rituximab: A case report. Eur J Rheumatol. 2017;4(2):145-147doi: 10.5152/eurjrheum.2017.160073.
Doğru, A., Ugan, Y., Şahin, M., Karahan, N., & Tunç, �. �. E. (2017). Catastrophic antiphospholipid syndrome treated with rituximab: A case report. European journal of rheumatology, 4(2), 145-147. https://doi.org/10.5152/eurjrheum.2017.160073
Doğru, Atalay, et al. "Catastrophic antiphospholipid syndrome treated with rituximab: A case report." European journal of rheumatology vol. 4,2 (2017): 145-147. doi: https://doi.org/10.5152/eurjrheum.2017.160073
Doğru A, Ugan Y, Şahin M, Karahan N, Tunç ŞE. Catastrophic antiphospholipid syndrome treated with rituximab: A case report. Eur J Rheumatol. 2017 Jun;4(2):145-147. doi: 10.5152/eurjrheum.2017.160073. Epub 2017 Jun 01. PMID: 28638691; PMCID: PMC5473453.
Copy Download .nbib Format: NLM
Share it on

Eur J Rheumatol. 2017 Jun;4(2):145-147. doi: 10.5152/eurjrheum.2017.160073. Epub 2017 Jun 01.

Catastrophic antiphospholipid syndrome treated with rituximab: A case report.

European journal of rheumatology

Atalay Doğru, Yunus Ugan, Mehmet Şahin, Nermin Karahan, Şevket Ercan Tunç

Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Süleyman Demirel University School of Medicine, Isparta, Turkey.
  2. Department of Pathology, Süleyman Demirel University School of Medicine, Isparta, Turkey.

PMID: 28638691 PMCID: PMC5473453 DOI: 10.5152/eurjrheum.2017.160073

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a rare and fatal condition that is characterized by diffuse venous and/or arterial thromboembolism within a short period of time and histopathological confirmation of small-vessel occlusion in at least one organ or tissue in the presence of positive antiphospholipid antibodies. Here we report the case of a 19-year-old woman with CAPS. During the first week of her hospitalization, she was diagnosed with CAPS on the basis of skin necrosis, pulmonary artery thrombosis, cerebral venous sinus thrombosis, and positive lupus anticoagulant. She was treated with corticosteroids, intravenous immunoglobulins, plasmapheresis, and anticoagulants. Forty days after the onset of CAPS, cutaneous lesions were recurred during skin surgery. She required a high dose of corticosteroids, intravenous immunoglobulins, and rituximab. No further thrombotic events occurred. Rituximab may be an effective treatment option for patients with CAPS.

Keywords: Antiphospholipid syndrome; plasmapheresis; rituximab; skin necrosis

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

References

  1. Ther Adv Musculoskelet Dis. 2015 Feb;7(1):26-30 - PubMed
  2. Lupus. 2016 Dec;25(14 ):1520-1531 - PubMed
  3. Autoimmun Rev. 2014 Jul;13(7):699-707 - PubMed
  4. J Rheumatol. 2007 May;34(5):923-6 - PubMed
  5. Autoimmun Rev. 2013 Sep;12(11):1085-90 - PubMed
  6. Acta Reumatol Port. 2015 Apr-Jun;40(2):169-75 - PubMed
  7. Blood. 2015 Sep 10;126(11):1285-93 - PubMed

Publication Types